Gut Microbiota Reconstruction for NSCLC Immunotherapy
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
In this study, patients with locally advanced or metastatic NSCLC after first-line treatment
with PD-1/PDL-1 monoclonal antibody will be treated with Gut Microbiota reconstruction(such
as FMT) combined with PD-1/PDL-1 monoclonal antibody. We will evaluate the safety of FMT in
the treatment of advanced NSCLC, and analyze the effect of FMT on intestinal flora and
immunophenotype of patients.